255 related articles for article (PubMed ID: 11331474)
1. Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth.
Hotz HG; Reber HA; Hotz B; Sanghavi PC; Yu T; Foitzik T; Buhr HJ; Hines OJ
J Gastrointest Surg; 2001; 5(2):131-8. PubMed ID: 11331474
[TBL] [Abstract][Full Text] [Related]
2. Anti-angiogenic treatment for peritoneal dissemination of pancreas adenocarcinoma: a study using TNP-470.
Kato H; Ishikura H; Kawarada Y; Furuya M; Kondo S; Kato H; Yoshiki T
Jpn J Cancer Res; 2001 Jan; 92(1):67-73. PubMed ID: 11173546
[TBL] [Abstract][Full Text] [Related]
3. Specific targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion protein reduces angiogenesis and growth of pancreatic cancer.
Hotz HG; Gill PS; Masood R; Hotz B; Buhr HJ; Foitzik T; Hines OJ; Reber HA
J Gastrointest Surg; 2002; 6(2):159-66; discussion 166. PubMed ID: 11992800
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of the antiangiogenic agent TNP-470 on establishment and growth of hematogenous metastasis of human pancreatic carcinoma in SCID beige mice in vivo.
Kawarada Y; Ishikura H; Kishimoto T; Saito K; Takahashi T; Kato H; Yoshiki T
Pancreas; 1997 Oct; 15(3):251-7. PubMed ID: 9336788
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of liver metastasis of human pancreatic carcinoma by angiogenesis inhibitor TNP-470 in combination with cisplatin.
Shishido T; Yasoshima T; Denno R; Mukaiya M; Sato N; Hirata K
Jpn J Cancer Res; 1998 Sep; 89(9):963-9. PubMed ID: 9818033
[TBL] [Abstract][Full Text] [Related]
6. Growth inhibition of liver metastases by the anti-angiogenic drug TNP-470.
Gervaz P; Scholl B; Padrun V; Gillet M
Liver; 2000 Apr; 20(2):108-13. PubMed ID: 10847478
[TBL] [Abstract][Full Text] [Related]
7. Characterization of TNP-470-induced modifications to cell functions in HUVEC and cancer cells.
Farinelle S; Malonne H; Chaboteaux C; Decaestecker C; Dedecker R; Gras T; Darro F; Fontaine J; Atassi G; Kiss R
J Pharmacol Toxicol Methods; 2000; 43(1):15-24. PubMed ID: 11091126
[TBL] [Abstract][Full Text] [Related]
8. Angiogenic potential of prostate carcinoma cells overexpressing bcl-2.
Fernandez A; Udagawa T; Schwesinger C; Beecken W; Achilles-Gerte E; McDonnell T; D'Amato R
J Natl Cancer Inst; 2001 Feb; 93(3):208-13. PubMed ID: 11158189
[TBL] [Abstract][Full Text] [Related]
9. Contribution of angiogenesis to the progression of colon cancer: possible inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and hepatic metastasis.
Takatsuka S; Yamada N; Sawada T; Ogawa Y; Maeda K; Ohira M; Ishikawa T; Nishino H; Seki S; Hirakawa-YS Chung K
Int J Oncol; 2000 Aug; 17(2):253-8. PubMed ID: 10891532
[TBL] [Abstract][Full Text] [Related]
10. [Inhibitory effects of TNP-470 in combination with 5-fluorouracil on growth of human colon cancer].
Fan YF; Huang ZH; Nie J
Ai Zheng; 2002 Dec; 21(12):1319-23. PubMed ID: 12520739
[TBL] [Abstract][Full Text] [Related]
11. Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder.
Inoue K; Chikazawa M; Fukata S; Yoshikawa C; Shuin T
Clin Cancer Res; 2002 Jul; 8(7):2389-98. PubMed ID: 12114444
[TBL] [Abstract][Full Text] [Related]
12. [Implication of vascular endothelial growth factor (VEGF) in human head and neck cancer].
Ueno Y
Nihon Jibiinkoka Gakkai Kaiho; 2006 Mar; 109(3):163-70. PubMed ID: 16615431
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of vascular endothelial growth factor blockade and matrix metalloproteinase inhibition as a combination therapy for experimental human pancreatic cancer.
Hotz HG; Hines OJ; Hotz B; Foitzik T; Buhr HJ; Reber HA
J Gastrointest Surg; 2003 Feb; 7(2):220-7; discussion 227-8. PubMed ID: 12600446
[TBL] [Abstract][Full Text] [Related]
14. VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer.
Hotz HG; Hines OJ; Masood R; Hotz B; Foitzik T; Buhr HJ; Gill PS; Reber HA
Surgery; 2005 Feb; 137(2):192-9. PubMed ID: 15674201
[TBL] [Abstract][Full Text] [Related]
15. TNP-470 promotes initial vascular sprouting in xenograft tumors.
Huang J; Frischer JS; New T; Kim ES; Serur A; Lee A; Kadenhe-Chiwishe A; Pollyea DA; Yokoi A; Holash J; Yancopoulos GD; Kandel JJ; Yamashiro DJ
Mol Cancer Ther; 2004 Mar; 3(3):335-43. PubMed ID: 15026554
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of inflammatory corneal angiogenesis by TNP-470.
Joussen AM; Beecken WD; Moromizato Y; Schwartz A; Kirchhof B; Poulaki V
Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2510-6. PubMed ID: 11581191
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis inhibitor TNP-470 suppresses growth of peritoneal disseminating foci of human colon cancer line Lovo.
Fan YF; Huang ZH
World J Gastroenterol; 2002 Oct; 8(5):853-6. PubMed ID: 12378629
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with tumor-lysate pulsed dendritic cells and antiangiogenic drug TNP-470 for mouse pancreatic cancer.
Miyazaki J; Tsuzuki Y; Matsuzaki K; Hokari R; Okada Y; Kawaguchi A; Nagao S; Itoh K; Miura S
Int J Cancer; 2005 Nov; 117(3):499-505. PubMed ID: 15906361
[TBL] [Abstract][Full Text] [Related]
19. Suppression of tumor growth and downregulation of platelet-derived endothelial cell growth factor / thymidine phosphorylase in tumor cells by angiogenesis inhibitor TNP-470.
Mori J; Haisa M; Naomoto Y; Takaoka M; Kimura M; Yamatsuji T; Notohara K; Tanaka N
Jpn J Cancer Res; 2000 Jun; 91(6):643-50. PubMed ID: 10874218
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of antiangiogenic therapy with TNP-470 in superficial and invasive bladder cancer models in mice.
Beecken WD; Fernandez A; Panigrahy D; Achilles EG; Kisker O; Flynn E; Joussen AM; Folkman J; Shing Y
Urology; 2000 Sep; 56(3):521-6. PubMed ID: 10962337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
